

Appl. No. : 09/830,703
Filed : April 26, 2001

made in order to more distinctly claim the present invention. Support for the amendment to Claim 1 may be found in Tables 1 and 2, on pages 18 and 19, respectively, as well as on page 8 lines 17-19 of the specification. The specific amendments to the application are shown on a separate set of pages attached hereto and entitled **VERSION WITH MARKINGS TO SHOW CHANGES MADE**, which follows the signature page of this Amendment. On this set of pages, the insertions and **[deletions]** are indicated.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410. A duplicate copy of this sheet is enclosed.


Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 6/5/01

By: Mark R. Benedict
Mark/R. Benedict
Registration No. 44,531
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660

Appl. No. : 09/830,703
Filed : April 26, 2001



VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

The paragraph beginning on page 9, line 12, has been deleted and rewritten as follows:

To obtain at least a transgenic non-human animal as a model for neurodegenerative diseases, the natural occurring sequence of the parkin gene in this animal may be replaced on one or both alleles of the chromosomes by a sequence of mPark2, containing mutations or deletions according to the present invention. These animals produce either less or **[more]** less active or no parkin protein.

IN THE CLAIMS:

1. (Twice Amended) An isolated or purified polynucleotide encoding a **[mutant]** mouse parkin2 protein, or a homolog thereof, containing mutations or deletions in at least one of the exons 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, or 12, or containing a frame-shift mutation in exon 4, wherein said **[mutant]** mutation causes Parkinson's disease.